Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,034
+$4,296 QoQ
Shares Held
251
+945.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ROYAL BANK OF CANADA holds $1,974,352,961 across 412 Biotechnology names. LYEL ranks #236 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,111,871 | $496,494,870 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
3,801,815 | $285,478,282 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
351,171 | $271,328,756 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
791,515 | $261,888,563 | |
| 5 | INCY |
Incyte Corp
|
1,054,123 | $99,214,053 | |
| 6 | INSM |
INSMED Inc
|
523,101 | $85,537,473 | |
| 7 | MRNA |
Moderna, Inc.
|
999,340 | $50,766,470 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
658,290 | $42,545,279 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,034 | 251 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $738 | 24 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $67,996 | 4,187 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $220 | 25 | Shares | Defined | 2025-11-21 | |
| No filing history on record for this holder in this stock. | ||||||